Management strategies for hepatitis C virus infection in children

Pediatric Drugs

Volumn 10, Issue 6, 2008, Pages 357-365

  Davison, Suzanne M ^a   Kelly, Deirdre A ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Children; Hepatitis C, diagnosis; Hepatitis C, treatment; Interferon alpha 2b, therapeutic use; Interferon alpha, therapeutic use; Peginterferon alfa 2a, therapeutic use; Peginterferon alfa 2b ribavirin, therapeutic use; Ribavirin, therapeutic use

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; HUMAN MONOCLONAL ANTIBODY; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TARIBAVIRIN;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; CHILD; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FLU LIKE SYNDROME; GENE THERAPY; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTHYROIDISM; INSOMNIA; IRRITABILITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MONOTHERAPY; MOOD DISORDER; MORBIDITY; MORTALITY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RNA INTERFERENCE; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TERATOGENICITY; THALASSEMIA; THYROID FUNCTION; UNITED KINGDOM; VERTICAL TRANSMISSION; VIRUS GENOME; WEIGHT REDUCTION;

ADULT; ANEMIA; ANTIVIRAL AGENTS; CHILD; COMORBIDITY; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; RIBAVIRIN;

EID: 55949136965     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/0148581-200810060-00003     Document Type: Review

References (51)

1. Health Protection Agency. Hepatitis C in England: annual report. London: Health Protection Agency Centre for Infections, December 2006
2. NHS. Hepatitis C awareness [online]. Available from URL: http://www.nhs.uk/Livewell/hepatitisc/Pages/Hepatitischome.aspx [Accessed 2008 Oct 13]
3. Jhaveri R, Grant W, Kauf TL, et al. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr 2006; 148: 353-8
4. Sinha M, Das A. Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children. Pediatr Infect Dis J 2000; 19 (1): 23-30
5. Ades AE, Parker S, Walker J, et al. HCV prevalence in pregnant women in the UK. Epidemiol Infect 2000; 125 (2): 399-405
6. Hutchinson SJ, Goldberg DJ, King M, et al. Hepatitis C virus among childbearing women in Scotland: prevalence, deprivation and diagnosis. Gut 2004; 53: 593-8
7. Hoofnagle JH, Mullen KD, Jones B, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986; 315: 1575-8
8. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-72
9. National Institute for Health and Clinical Excellence. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. London: NICE, Jan 2004 [online]. Available from URL: http://www.nice.org.uk/Guidance/TA75 [Accessed 2008 Sep 27]
10. National Institute for Health and Clinical Excellence. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. London: NICE, Aug 2006 [online]. Available from URL: http://www.nice.org.uk/Guidance/TA106 Accessed 2008 Sep 27]
11. Lau JY, Tam RC, Liang J, et al. Mechanism of action of ribavirin in combination treatment of chronic HCV infection. Hepatology 2002; 35 (5): 1002-9
12. Reichard O, Norkrans G, Fryden A, et al. Randomised, double-blind, placebo-controlled trial of interferon a-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7
13. McHutchison JG, Gordon SC, Schiff ER. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92
14. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65
15. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13): 975-82
16. Neal KR, on behalf of the Trent Hepatitis C Study Group. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007; 56: 1098-104
17. Soga K, Shibasaki K, Aoyagi Y. Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatogastroenterology 2005; 52 (64): 1154-8
18. Jacobson KR, Murray K, Zellos A, et al. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 34: 52-8
19. Schwarz KB, Mohan P, Narkewicz MR, et al. Safety, efficacy and pharmacokinetics of peginterferon a2a (40 kd) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2006; 43: 499-505
20. Gonzalez-Peralta RP, Kelly DA, Haber B, et al. Interferon alfa-2b in combination with ribavirin for children with chronic hepatitis C in children: efficacy, safety and pharmacokinetics. Hepatology 2005 Nov; 42 (5): 1010-8
21. Wirth S, Gehring S, Lang T, et al. Treatment with alfa-interferon and ribavirin improves the response rate in children with chronic hepatitis C [abstract]. J Pediatr Gastroenterol Nutr 2002; 34: 439
22. Suoglu D, Elkabes B, Sokucu S, et al. Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C? J Pediatr Gastroenterol Nutr 2002; 34: 199-206
23. Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41: 1013-8
24. PEDS-C. A clinical trial for children with hepatitis C virus [online]. Available from URL: http://www.pedsc.org/ [Accessed 2008 Oct 13]
25. McHutchison JG, Manns MP, Brown RS, et al. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007; 102: 880-9
26. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype 1 infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9
27. Davison SM, Mieli-Vergani G, Sira J, et al. Perinatal hepatitis C virus infection: diagnosis and management. Arch Dis Child 2006; 91: 781-5
28. Booth JCL, O'Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut 2001; 49: 1-21
29. Reddy KR, Shiffman M, Morgan T, et al. Impact of ribavirin dose reductions in HCV genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5: 124-9
30. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132: 103-12
31. Artan R, Akcam M, Yilmaz A, et al. Interferon alpha monotherapy for chronic hepatitis C viral infection in thalassemics and hemodialysis patients. J Chemother 2005; 17 (6): 651-5
32. Inati A, Taher A, Ghorra S, et al. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. Br J Haematol 2005; 130: 644-6
33. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830-6
34. Walter T, Dumortier J, Guillaud O, et al. Factors influencing the progression of fibrosis in patents with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single centre. Liver Transpl 2007; 13: 294-301
35. Yilmaz N, Shiffman NL, Stravitz RT, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007; 13: 975-83
36. Barshes NR, Udell IW, Lee TC, et al. The natural history of hepatitis C virus in pediatric liver transplant recipients. Liver Transpl 2006; 12: 1119-23
37. Sharma P, Marrero J, Fontana RJ, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13: 1100-8
38. Stravitz RT, Shiffman ML, Sanyal AJ, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004; 10: 850-8
39. Saab S, Kalmaz D, Gajjar N, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver transpl 2004; 10: 859-67
40. Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 2006; 57 (1): 8-13
41. Bain VG, Kaita KD, Yoshida EM, et al. A phase 2 study to evaluate the antiviral activity, safety and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis c patients. J Hepatol 2006; 44 (4): 671-8
42. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005; 436: 953-60
43. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase 1b, placebo-controlled, randomized study. Gastroenterology 2006; 131 (4): 997-1002
44. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects and complications. Gut 2006; 55: 1350-9
45. Schmitz V, Qian C, Ruiz J, et al. Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancy. Gut 2002; 50: 130-5
46. Grimm D, Kay MA. Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther 2006; 13: 563-75
47. Galun E, Terrault NA, Eren R, et al. Clinical evaluation (phase 1) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J Hepatol 2007; 46 (1): 37-44
48. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med 2005; 11: 791-6
49. Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005; 102: 9294-9
50. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-6
51. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005; 436: 961-6